We conducted a retrospective analysis of all allogeneic stem cell transplantation (ASCT) patients started on extracorporeal photopheresis (ECP) for the management of steroid-dependent (SD) or steroid-refractory (SR) cutaneous chronic graft-versus-host disease (cGVHD) following ASCT during a 36-month period (9/98-8/01). Only SD or SR patients who were treated by ECP after day 100 and who received at least 4 weeks of ECP were considered evaluable for this analysis. Out of 64 ASCT patients reviewed, 32 patients met the inclusion criteria. All 32 patients had been previously treated with systemic corticosteroids with 11 (34%) being SR and 21 (66%) SD. Cutaneous cGVHD was extensive in 28 patients (88%) and was accompanied by visceral (hepatic, gastrointestinal) cGVHD in 23 patients (72%). The 32 evaluated patients had received a median of three prior therapies before ECP, most commonly systemic corticosteroids, tacrolimus, and mycophenolate mofetil. Patients received a median of 36 ECP sessions (range 12-98) over a median of 5.3 months (range 1-28), with a median of six sessions per month. The complete response (CR) rate was 22% (n ¼ 7) and the partial response rate was 34% (n ¼ 11). In all, 28 patients were on systemic corticosteroid therapy at ECP initiation and 18 patients achieved 50% dose reduction while on ECP, yielding a 64% steroid-sparing response rate. Of seven CRs, five are ongoing. A total of 11 (34%) patients have died after ECP, with all cases due to visceral cGVHD or cGVHD-related infectious complications. All 21 surviving patients remain on at least some immunosuppressive cGVHD therapy (including ECP in eight). Overall, ECP displays a substantial response rate and, in particular, steroid-sparing activity in SR/SD extensive cutaneous cGVHD. However, most patients continue to require at least some chronic therapy and cGVHD-related morbidity and mortality remain high.
host disease; chronic GVHD; allogeneic stem cell transplantation While allogeneic stem cell transplantation (ASCT) has become a major therapeutic option for patients with leukemia, lymphoma, and other cancers, its effectiveness is often limited by acute and chronic graft-versus-host disease (GVHD). Improvements in the effectiveness of acute GVHD (aGVHD) prophylaxis and treatment have led to lengthened survival of ASCT patients, and consequently an increased opportunity for the development of chronic GVHD (cGVHD). Currently, cGVHD affects 30-50% of ASCT patients surviving longer than 6 months, and leads to mortality in 10-80% of cases, depending on adequacy of treatment and risk factors. [1] [2] [3] Cutaneous involvement is the most common manifestation, occurring in 90-100% of cGVHD patients. 3, 4 Chronic cutaneous GVHD lesions are typically either lichenoid or sclerodermoid, and may be a cause of substantial morbidity and disability. 4 Systemic corticosteroids constitute first-line therapy for cutaneous (and systemic) cGVHD and produce approximately 30% complete response. 3 However, disease is often steroid-refractory (SR) and resistant to second-line therapies such as cyclosporine, antithymocyte globulin, thalidomide, PUVA, and tacrolimus. Other cases are steroiddependent (SD) (ie initially responsive to corticosteroids, but with disease relapse or flare upon steroid taper), subjecting patients to long-term corticosteroid toxicity. Despite the availability of many therapeutic options, these SR and SD cases of cutaneous cGVHD remain a formidable challenge.
Extracorporeal photopheresis (ECP), an apheresis procedure incorporating ultraviolet (UV)-A irradiation of photosensitized peripheral blood mononuclear cells, has been used to treat refractory cGVHD with promising results. [5] [6] [7] [8] [9] [10] [11] The procedure, also referred to as extracorporeal photoimmune therapy, was first evaluated by Edelson et al in the late 1980s for the treatment of erythrodermic cutaneous T-cell lymphoma and was found to provide high response rates and improve overall survival for the disease. [12] [13] [14] The use of ECP has since been expanded for the treatment of other T-cell-mediated diseases, including GVHD and autoimmune diseases. The mechanism of action of ECP is not well delineated, although it appears to involve modulation of immunoregulatory responses, and inactivation and apoptosis of T-cell lymphocytes. It is thought that ECP treatment and the effects of UV irradiation induce apoptotic destruction of pathogenic T cells, the products of which activate antigen-presenting cells. 15, 16 The immune response activation is thought to further stimulate a CD8+ T-cell anticlonotypic immune reaction against pathogenic T-cell clones. 16 There is also evidence that ECP induces immunomodulation that shifts cytokine profiles from a Th1 to a Th2 response. 17 In previous reports, ECP has been shown to improve cutaneous cGVHD and reduce the need for corticosteroid and immunosuppressive therapies. Greinix et al 8 reported complete responses (CRs) in 12 of 15 (80%) cutaneous cGVHD patients. However, most previously reported experiences with ECP in cutaneous cGVHD treatment have been case reports or have examined a limited number of patients treated for short periods of time. The aim of this study was to examine the feasibility and results of ECP in the treatment of SR or SD cutaneous cGVHD at our institution.
Patients and methods
We performed a retrospective analysis of all ASCT patients at our institution, including all allogeneic bone marrow and peripheral stem cell transplant patients, who were started on ECP (Therakos UVAR s or UVAR XTS s system) for the management of SR or SD cutaneous cGVHD during a 36-month period (9/98-8/01). Patients were defined as having cGVHD if signs and symptoms of GVHD manifested after day 100 post-transplantation. Biopsies were frequently, but not always, performed to confirm the diagnosis of cGVHD. SR cGVHD was defined as disease that failed to respond to standard doses (1 mg/kg prednisone or equivalent) of systemic corticosteroids, and SD cGVHD was defined as disease that had an initial response followed by a cGVHD flare upon steroid taper.
Patients were also characterized according to cGVHD extent and severity, type of cGVHD onset, and prognostic risk. Disease was classified as limited if there was limited skin disease with or without hepatic involvement, and extensive if there was generalized skin cGVHD alone or multiorgan involvement with limited or generalized skin disease. 4, 18, 19 Onset of disease was defined as progressive if cGVHD developed as a continuation of aGVHD, quiescent if cGVHD developed after resolution of previous aGVHD, and de novo if cGVHD developed without prior presentation of aGVHD. 4, 19, 20 Prognostically, patients were determined to have low vs high-risk disease based on thrombocytopenia with platelet levels greater than 100 Â 10 9 /l corresponding to low-risk disease, and less than 100 Â 10 9 /l corresponding to high-risk cGVHD. 18, 19, 21 Only SD or SR patients who began ECP after day 100 as primary treatment for cutaneous disease were evaluated. In addition, patients had to receive ECP for a duration of at least 4 weeks in order to be evaluable. The overall data were examined for ECP treatment duration, complete, partial, and steroid-sparing response rates, and overall and cGVHD-related mortality. Our response grading criteria defined CR as the complete resolution of all active skin involvement with or without residual clinically inactive skin lesions. Partial response (PR) was defined as improvement in skin rash and/or skin involvement on at least 50% of the body surface area. A steroid-sparing response (SS) was a 50% or more decrease in the systemic corticosteroid requirement between the beginning and end of ECP therapy.
Results

Patient population
Out of 64 ECP patients reviewed during this retrospective study, 32 met the criteria for evaluation. Detailed data on these 32 patients are presented in Table 1 , and include disease and treatment characteristics, response, and outcome. The other 32 patients were excluded as a result of ECP initiation before day 100 (n ¼ 17), lack of cutaneous involvement during the initiation of ECP therapy (n ¼ 4), receiving ECP therapy for less than 4 weeks (n ¼ 7), or no prior systemic corticosteroid therapy (n ¼ 4). Six patients whose ECP duration was less than 4 weeks were taken off therapy because of GVHD-related mortality. In addition, one patient was taken off therapy after the development of pancytopenia, which was thought to be unrelated to ECP therapy.
The demographics of the 32 evaluable patients are presented in Table 2 . There were two pediatric and 30 adult patients in the study population with ages ranging between 5 and 70 years and a median of 43. Approximately half of the patients (n ¼ 17) received ASCT for acute or chronic myelogenous leukemias, while two patients had myelodysplastic syndrome, one had aplastic anemia, one had sickle cell anemia, and 11 other patients had a variety of lymphomas. GVHD prophylaxis most commonly consisted of methotrexate and tacrolimus. Table 2 also displays the ASCT history of the patients studied with 63% of grafts coming from matched siblings. The number of bone marrow (n ¼ 15) and peripheral stem cell transplants (n ¼ 17) was nearly equal in the study population.
cGVHD characteristics and treatment history
Overall, a majority of the patients examined had aggressive and treatment-refractory cGVHD, with 18 patients (56%) having progressive and quiescent forms of the disease (Table 3 ). Of the 32 evaluable patients, 28 had extensive disease and four had limited disease based on the criteria described previously. The distribution between predominantly lichenoid (n ¼ 15) and sclerodermoid (n ¼ 17) cutaneous involvement was similar. All 32 patients received systemic corticosteroid therapy prior to beginning ECP: 11 (34%) had SR disease and 21 (66%) had SD disease. Based on thrombocytopenia (platelets o100 Â 10 9 /l), 16 patients (50%) were considered to have disease that was high risk for mortality. A majority of the patients were also heavily ECP in the management of cutaneous chronic GVHD N Apisarnthanarax et al ECP in the management of cutaneous chronic GVHD N Apisarnthanarax et al pretreated with a median of three prior cGVHD treatments (range 1-5 treatments). The most frequent prior treatments included methylprednisolone or prednisone, tacrolimus, mycophenolate mofetil, and infliximab, in decreasing order of frequency (Table 4 ). In addition, 18 of the 32 patients (56%) were also on concomitant therapies (besides tacrolimus and methylprednisolone) at the initiation of ECP, including mycophenolate mofetil (n ¼ 8), rapamycin (n ¼ 6), thalidomide (n ¼ 5), deoxycoformycin (n ¼ 2), infliximab (n ¼ 4), cyclosporine A (n ¼ 3), humanized anti-TAC antibody (n ¼ 1), and plaquenil (n ¼ 1).
ECP treatment: response rates and patient outcome
Since ECP was not given in a standardized fashion over the 36-month study period, ECP treatments were given on varying schedules, with more sessions usually given during the first weeks and months of therapy, depending on the severity of cGVHD. ECP was begun at a median of 13.1 months (range 0.3-51.2 months) after the onset of cGVHD and 26.2 months (range 3.6-62.5 months) after transplantation. The median number of ECP sessions was six per month with a median of 34 total sessions (Table 5) . Therapy lasted a median of 5.3 months. Eight patients remain active on ECP therapy, with a median treatment duration of 10.8 months at last follow-up. Discontinuation of therapy occurred as a result of lack of response or plateau in response (n ¼ 10), resolution of disease (n ¼ 5), death related to visceral GVHD progression or infection (n ¼ 5), access difficulty (n ¼ 1), central-line infection (n ¼ 1), fluid overload (n ¼ 1), or deep venous thrombosis (n ¼ 1). ECP was added and given concomitantly with prior therapies in most patients. Patients received tacrolimus along with ECP in all but four cases.
In this cutaneous cGVHD population, ECP therapy produced a 56% overall response (OR) rate and a 22% CR rate (Table 6 ). CRs were seen in three patients with limited and four patients with extensive cutaneous cGVHD involvement. Out of seven patients with CR responses, two patients remain active on ECP therapy after 14.3 and 27.9 months. In other cases, ECP was discontinued after CR was achieved. Cutaneous remission was maintained in all but two CR patients, who exhibited recurrence of cutaneous cGVHD 2.8 and 5.7 months after discontinuation of ECP. These relapsed patients did not receive repeat courses of ECP, but were controlled on methylprednisolone and tacrolimus. One of these patients had myelodysplastic syndrome and died from infection and the development of AML. One other CR patient died from progression of visceral disease, although cutaneous cGVHD remained in remission at the time of death. In terms of amount of ECP treatment, responding and nonresponding patients received approximately the same number of treatment sessions per month: responding patients received a median of six treatments and nonresponders received seven treatments per month.
Among subpopulations of treated patients, the OR rates of patients with sclerodermoid (n ¼ 17) and lichenoid (n ¼ 15) disease were 59 and 53%, respectively. Three patients with predominantly sclerodermoid and four patients with predominantly lichenoid disease exhibited CR responses. The OR rates of patients with and without concomitant visceral involvement were also similar: 57% OR for 23 patients with visceral disease and 56% OR for nine patients without visceral disease. Response and outcome based on the onset of cGVHD were observed as In addition to clinical cutaneous responses, 18 of 28 patients (64%) who were on systemic corticosteroids at the start of ECP therapy were able to reduce their initial corticosteroid dose by 50%, thereby achieving an SS. Four of the SSs were seen in patients who had no cutaneous response to ECP therapy. Of the 18 patients achieving an SS, six discontinued corticosteroid therapy completely. While four of these patients remain on active ECP therapy, two patients have been able to remain off from corticosteroids at follow-up 2 and 6 months after ECP discontinuation.
Overall, 27 of 32 patients had evidence of cGVHD, either cutaneous or visceral, after completion of ECP therapy. Death occurred in 11 of 32 patients (34%), with the cause of death being visceral cGVHD (n ¼ 5) or infectious complications related to the disease (n ¼ 6). Despite the responses seen with ECP therapy, all 21 surviving patients remain on some kind of cGVHD therapy post-ECP for cutaneous and/or visceral cGVHD.
Side effects and toxicity
In general, ECP was very well tolerated. Few major complications were observed and were usually related to the long-term indwelling central venous apheresis (hemodialysis-type) catheters that were needed to maintain the long-term vascular access required for the treatment. Treatment complications leading to discontinuation of ECP were observed in three patients and consisted of one episode each of catheter line infection, fluid overload, and venous thrombosis at the catheter site. Besides the episodes of line infection and venous thrombosis, pheresis catheter replacement was generally not required. Furthermore, decreases in blood cell counts were not observed in the patients and blood product support was not required during therapy. ECP is often associated with minor treatment-related side effects such as transient hypotension during the procedure, post-reinfusion fever and erythema, and nausea related to oral psoralen ingestion (in patients treated using the Therakos UVAR system). Little attention was devoted to these transient side effects in this study population, since they did not last beyond the treatment sessions and were not significant or treatment limiting.
Discussion
To the best of our knowledge, the data on the 32 patients reported in this study are the largest single-institution analyses of ECP therapy for cutaneous cGVHD. Although it would have been of interest, an analysis of concomitant visceral disease response was not among our goals because cutaneous cGVHD was the primary focus of this analysis and also because of the lack of well-accepted response criteria for visceral cGVHD. Many reports of ECP therapy for cutaneous cGVHD in the literature have been limited to case reports or prospective studies on smaller number of patients, and direct comparisons are difficult owing to differences in study populations. The nonrandomized trial by Greinix et al 8 on 15 cutaneous cGVHD patients has produced the highest reported response rates (100% OR, 80% CR). In addition to differences in sample size, the differences in response rates between this study (56% OR, 22% CR) and those of Greinix et al may be, at least partly, explained by differences in study populations. The population of Greinix et al had three (20%) high-risk cGVHD patients based on thrombocytopenia, as opposed to 50% of the population in this study. Whereas 28 of 32 patients in this study had generalized cutaneous involvement, Greinix et al did not disclose the extent of cutaneous involvement.
The patient population in this study is also generally more treatment refractory with a median of three prior treatments before ECP as opposed to two in that of Greinix et al. The higher number of prior therapies -particularly immunosuppressive therapies -seen in these patients may portend lower response rates to ECP. It has been postulated that the benefits of ECP are maximized when the immune system remains intact. This observation was originally made from the experience of using ECP in the treatment of erythrodermic cutaneous T-cell lymphoma patients. 13, 22 Thus, it is suspected that GVHD patients, who have received multiple immunosuppressive therapies, might not respond as well to ECP as those who have received fewer, or no such therapy. Child et al 9 noted a shorter median time between the onset of GVHD and the start of ECP therapy (with an implication of fewer refractory therapies) in patients who had greater cutaneous improvement. Likewise, Dall' Amico et al 5 observed that the only one of four cGVHD patients who did not respond to ECP therapy had a longer duration between disease onset and start of therapy. With regard to these current data, the duration between onset of cGVHD and ECP was 13.1 months in nonresponders and 5.9 months in complete responders, which corresponds to trends from previous observations. However, this trend does not hold true when partial responders are considered, as the duration between cGVHD and ECP onset was 17 months for patients with a PR. From these observations, it appears that although early initiation of ECP could be associated with higher CR rates, PRs are still frequently seen in patients who are initiated much later. It is also possible that these PR patients, five of whom were started on ECP 45-50 months after cGVHD onset, would have had more pronounced responses had they been started on ECP earlier.
While the ECP treatment regimen varied between patients, it appears that the number of treatments given per month may not affect response rates, since the median number of treatments given was similar between responding and nonresponding groups of patients. Thus, based upon these limited data, variations in the ECP treatment regimen may not have a significant impact on cutaneous cGVHD response. Transfusion history and onset type of cGVHD affected response and mortality as expected. Patients receiving sibling-matched stem cell transplants fared better than patients receiving MUD transplants. While severity of aGVHD was not evaluated, correlations may be drawn with the type of cGVHD onset. In these subgroups, patients with progressive cGVHD (disease progressing from aGVHD) fared the worst with 47% mortality, whereas patients with de novo onset cGVHD (no prior history of aGVHD) had a mortality of 21% and high response rates (71% OR).
CRs were durable in five of seven patients achieving CR on this study. The two relapses could be attributed to discontinuation of ECP therapy, although it cannot be ascertained whether the relapses would have occurred nevertheless. Three of the CRs remain durable while off of ECP therapy, while the other two patients remain in remission while on active therapy. Death occurred in 34% of patients, as a result of visceral GVHD progression or infection. While responses of visceral disease were not formally studied, it appears that visceral GVHD remains a prevalent cause of mortality and morbidity even after cutaneous disease response.
Few side effects were seen with ECP therapy, and longterm therapy was generally well tolerated. Central venous access problems caused interruption of therapy in two patients, and central line infection, a risk of long-term ECP therapy, occurred in only one patient who recovered. The favorable side-effect profile of ECP therapy highlights its advantages over other cGVHD therapies, especially those that induce more profound immunosuppression.
While these data appear promising, we acknowledge the limitations of this study, mainly its retrospective nature, as well as the difficulty of isolating the contribution of ECP in patients receiving multiple concomitant therapies. Nevertheless, it appears that ECP displays activity in extensive SR and SD cutaneous cGVHD with substantial response rates and steroid-sparing activity, even when most patients continue to require at least some chronic therapy, and cGVHD-related mortality remains high. These data indicate that ECP may play an adjunct role in the management of complex cGVHD patients. In addition, because of its low toxicity profile, ECP is a feasible treatment modality for cGVHD patients and can be carried out for extended periods of time (ie, several months). The greatest benefit of ECP may result from its steroid-sparing properties, since long-term corticosteroid use is a source of substantial morbidity and mortality in this population.
While ECP does show activity in cGVHD, there is still considerable room for improvement in the management of these patients. Every effort should be made to carry out further study of ECP in a prospective randomized trial setting. Future studies should also evaluate the benefit of starting ECP earlier in the cGVHD treatment process.
